As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Verve Therapeutics with a Buy rating and $29 price target, citing the company’s "cutting-edge gene-editing technology, clinically validated non-viral delivery modalities, and genetic targets where biology is known and already proven." The firm acknowledges some commercial questions that will need to be answered, but it says it accounted for that with "conservative market share assumptions" even despite its conservatism it sees the potential for combined peak sales of greater than $5B for lead programs VERVE-101 and VERVE-201.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics initiated with a Buy at Canaccord
- Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
- Verve Therapeutics reports new data from study of VERVE-201
- Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
- Verve Therapeutics reports Q4 EPS (67c), consensus (76c)
